Don't know if everyone caught this in the article, as it was almost at the end of it:

Pfizer executives said they were researching “rebound” COVID-19 cases in which some patients who took Paxlovid have reported renewed symptoms.

But company officials said the data thus far suggests that the amount of cases is small and may have to do with unusual patient characteristics rather than the drug itself.

Tada, like everyone else, I can't wait to get a peek at some data from our trial! So much potential, so much disappointment from our wannabe!

So, if my memory serves me correctly, someone (you???) had projected potentially a $400 share price for us when considering Pfizer's earlier SP rise and if we had a successful trial. What are we looking at now?